The study had certain problems from the clinical aspect:
(a) randomisation appeared to have failed, given that more proven bacterial infections were in the roxithromycin group they would have responded better to the antibiotics. (Some of the infections would be viral and would not respond).
(b) the analysis was based on "treatment completers", since the results did not relate to the original sample. Analysis of treatment completers my have biased the results.